Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation Into Corcept Therapeutics Incorporated (CORT)

Core Insights - Scott+Scott Attorneys at Law LLP is investigating Corcept Therapeutics Incorporated for potentially issuing misleading statements and failing to disclose material information to investors, which may violate federal securities laws [1][3]. Company Overview - Corcept Therapeutics is a pharmaceutical company focused on the discovery, development, and commercialization of drugs for severe metabolic, psychiatric, and oncologic disorders [2]. Recent Developments - On December 31, 2025, Corcept announced that the U.S. Food and Drug Administration issued a Complete Response Letter regarding the New Drug Application for relacorilant, indicating that additional evidence of effectiveness is required for a favorable benefit-risk assessment [3]. - Following the FDA's announcement, Corcept's stock price dropped over 50%, closing at $34.80 per share on the same day [3].